Continuing Education Credit Information for Clinical Updates from ASCO 2021 Webinar
Joint Accreditation Statement
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute of Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-21-3043-L01-P
Type of Activity: Knowledge
American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Hardware/Software Requirements
The webinar is accessed through Zoom. An internet connection and the system requirements are needed to access the webinar.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.
Educational Objectives
Upon completion of this program, participants will be able to:
- Summarize the most recent advances in cancer immunotherapy
- Analyze cutting-edge clinical trials to incorporate new research and techniques into clinical application for cancer immunotherapy
- Describe the role of clinical and investigational biomarkers in cancer immunotherapy